XOOMAR
Get a free API key

PMV Pharmaceuticals (PMVP)

PMV Pharmaceuticals on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.

Download CSV

2.3M

Short interest

settlement 2026-10-15

2.3

Days to cover

-1.3 days vs prior

19.2%

Short share of volume

2026-11-02

623

Fails to deliver

settlement 2026-10-09

Wed 11 Nov

Next earnings

estimated date

$0

Insider flow, 90 days

0 buys, 0 sells

As of 2026-11-02.

Short interest

FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSON

As of 15 October 2026, short interest in PMVP is 2,285,070 shares, down 634,061 shares over the last month. Over the last 48 readings it ranged from 751,556 shares (30 September 2025) to 3,255,236 shares (29 May 2026). At the reported average volume of 983K shares a day that is 2.3 days to cover.

Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/pmvp" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
PreviewDark previewAdd ?theme=dark to the src for a dark chart.
SettlementShares shortChangeAvg daily volumeDays to cover
2026-10-152,285,070-18.2%983,0262.32
2026-09-302,794,327-4.3%778,1473.59
2026-09-152,919,131+28.8%1,245,5752.34
2026-08-312,266,380+1.0%268,3078.45
2026-08-142,243,884-5.6%379,0045.92
2026-07-312,377,747-1.8%222,83810.67
2026-07-152,420,149-16.9%386,5066.26
2026-06-302,910,642+1.4%350,6348.30
2026-06-152,869,101-11.9%255,08411.25
2026-05-293,255,236+5.6%310,56310.48
2026-05-153,083,083+17.1%488,3186.31
2026-04-302,633,561+13.8%346,7187.60
2026-04-152,314,712+48.3%467,0664.96
2026-03-311,560,810+5.1%392,2223.98
2026-03-131,485,129+20.5%1,544,3591.00
2026-02-271,232,783-18.0%882,1071.40
2026-02-131,503,564-18.8%265,4925.66
2026-01-301,851,701+3.1%332,9265.56
2026-01-151,795,954+11.5%214,7908.36
2025-12-311,610,314+2.3%225,5867.14
2025-12-151,573,872+16.7%306,6925.13
2025-11-281,348,469-12.2%235,3865.73
2025-11-141,534,893+0.8%260,0875.90
2025-10-311,523,141-0.2%811,3811.88
2025-10-151,526,449+103.1%582,0452.62
2025-09-30751,556-1.2%820,0651.00
2025-09-15760,427-6.0%4,604,8201.00
2025-08-29808,829+0.6%489,2951.65
2025-08-15803,935-2.3%208,3643.86
2025-07-31822,807+6.9%320,7662.57
2025-07-15769,976-17.9%361,1852.13
2025-06-30937,875+8.0%128,2817.31
2025-06-13868,726+1.7%385,6802.25
2025-05-30854,290+1.6%343,2032.49
2025-05-15840,930-1.7%242,2923.47
2025-04-30855,425+2.0%89,2529.58
2025-04-15838,637+0.1%156,5795.36
2025-03-31837,513-5.5%87,0389.62
2025-03-14886,286+1.1%131,7196.73
2025-02-28876,945+1.4%141,9756.18
2025-02-14864,663+0.6%84,02910.29
2025-01-31859,149-37.6%148,1345.80
2025-01-151,377,498+2.5%181,4897.59
2024-12-311,343,614+2.5%171,5907.83
2024-12-131,311,516+48.0%275,1214.77
2024-11-29886,077+4.6%115,5857.67
2024-11-15846,901-0.0%196,0174.32
2024-10-31847,180-13.2%208,3144.07

Daily short volume

FINRA Reg SHO, the last 30 sessions. JSON

As of 2 November 2026, the short share of PMVP volume is 19.2%, down 39.1 points over the last five sessions. Over the last 30 readings it ranged from 14.8% (12 October 2026) to 70.4% (22 October 2026). The latest reading sits at the bottom of that range. The latest reading is 22.2 points below the 30-session average of 41.4%, on 204K shares reported.

DateShort volumeTotal volumeShort shareExempt
2026-11-0239K204K19.2%14,009
2026-10-30353K572K61.7%121,545
2026-10-2963K96K65.0%0
2026-10-28118K194K60.7%3,187
2026-10-27118K201K58.7%41,837
2026-10-26201K344K58.3%16,564
2026-10-2324K73K32.3%0
2026-10-2232K45K70.4%0
2026-10-2138K124K30.8%0
2026-10-20105K174K60.2%0
2026-10-1952K92K56.2%150
2026-10-1655K180K30.4%1,100
2026-10-1582K176K46.6%0
2026-10-1476K171K44.4%0
2026-10-1390K234K38.5%0
2026-10-1225K169K14.8%0
2026-10-0989K341K26.1%499
2026-10-0865K185K35.5%0
2026-10-07112K272K41.0%22,053
2026-10-06106K230K46.2%500
2026-10-05126K366K34.3%0
2026-10-02265K1.5M17.2%0
2026-10-01229K762K30.1%3,245
2026-09-30369K1.5M24.6%12,927
2026-09-29149K267K55.8%0
2026-09-2841K90K45.1%0
2026-09-2547K96K49.0%0
2026-09-2487K214K40.8%0
2026-09-2374K265K28.1%0
2026-09-2229K146K19.7%0

Fails to deliver

SEC, the last 30 settlement dates with a fail. JSON

As of 9 October 2026, the fails-to-deliver balance in PMVP is 623 shares, down 3,851 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (26 June 2026) to 585,504 shares (11 September 2025). The latest reading sits at the bottom of that range.

SettlementShares failedPriceValue
2026-10-09623$1.49$928
2026-08-274,474$1.31$6K
2026-08-131,839$1.26$2K
2026-06-261$1.15$1
2026-04-272,933$1.44$4K
2026-04-23325$1.48$481
2026-04-16629$1.41$887
2026-04-097,428$1.25$9K
2026-03-30203$1.31$266
2026-03-25197$1.39$274
2026-03-1316$1.58$25
2025-12-23745$1.25$931
2025-12-037,379$1.23$9K
2025-12-0235,764$1.29$46K
2025-11-1212$1.33$16
2025-10-067,443$1.44$11K
2025-09-16300$1.14$342
2025-09-1524,612$1.23$30K
2025-09-1224,612$1.23$30K
2025-09-11585,504$1.27$744K
2025-08-133,405$1.42$5K
2025-08-0810,768$1.45$16K
2025-08-0710,734$1.52$16K
2025-07-211,108$1.33$1K
2025-07-1846$1.33$61
2025-07-171,865$1.34$2K
2025-07-141,778$1.26$2K
2025-06-188,561$1.09$9K
2025-06-1643$1.08$46
2025-06-0910,093$0.97$10K

Insider trades

SEC Form 4, newest first. JSON

No open-market insider trades were reported for PMVP in the last 90 days. The most recent filings are listed below. Latest filing: Mack David Henry (President and CEO) on 2025-10-27.

DateInsiderTitleTypeSharesPriceValueOwned after
2025-10-27Mack David HenryPresident and CEOExercise or conversion221K$1.37$302K451K
2025-10-23OrbiMed Capital GP V LLCTenPercentOwnerSell1.0M$1.52$1.5M5.0M
2025-10-23ORBIMED ADVISORS LLC10% ownerSell1.0M$1.52$1.5M5.0M
2025-09-10ORBIMED ADVISORS LLC10% ownerSell500K$1.80$900K6.0M
2025-07-01Ticktin RobertGeneral Counsel & COOSell23K$1.06$25K99K
2025-07-01Mack David HenryPresident and CEOSell58K$1.06$62K536K
2025-07-01Jalota DeepikaChief Development OfficerSell33K$1.06$35K90K
2025-07-01Carulli MichaelChief Financial OfficerSell28K$1.06$30K60K
2025-01-03Mack David HenryPresident and CEOExercise or conversion18K$0.53$9K552K
2024-12-03Mack David HenryPresident and CEOExercise or conversion92K$0.53$49K534K
2024-09-11Carulli MichaelChief Financial OfficerSell3K$1.50$4K88K
2024-09-11Jalota DeepikaChief Development OfficerSell7K$1.50$11K118K
2024-01-18Mack David HenryPresident and CEOGrant164K$0.00$0442K
2024-01-18Carulli MichaelChief Financial OfficerGrant82K$0.00$091K
2024-01-18Jalota DeepikaChief Development OfficerGrant96K$0.00$0126K
2023-11-22OrbiMed Genesis GP LLCTenPercentOwnerSell88K$2.23$196K0
2023-11-10Mack David HenryPresident and CEOGift85K$0.00$0165K
2023-11-10Mack David HenryPresident and CEOGift85K$0.00$0279K
2023-10-18Mack David HenryPresident and CEOExercise or conversion198K$0.53$105K364K
2023-09-15Alland LeilaChief Medical OfficerSell6K$6.62$42K46K
2023-09-15Jalota DeepikaChief Development OfficerSell4K$6.62$27K30K
2023-08-07Mack David HenryPresident and CEOExercise or conversion86K$0.53$45K165K
2022-11-25Kung WinstonCOO, CFOGift3K$0.00$011K
2022-09-09Alland LeilaChief Medical OfficerGrant52K$0.00$052K
2022-09-09Jalota DeepikaSVP, Regulatory Affairs and QAGrant34K$0.00$034K
2022-05-26OrbiMed Capital GP V LLCTenPercentOwnerSell26K$15.93$418K88K
2022-04-27Mack David HenryPresident and CEOExercise or conversion33K$0.53$17K80K
2022-04-20Kung WinstonCOO, CFOExercise or conversion4K$3.22$13K11K
2022-03-31OrbiMed Genesis GP LLCTenPercentOwnerSell35K$21.17$730K0
2022-03-30OrbiMed Genesis GP LLCTenPercentOwnerSell75K$22.39$1.7M35K
2022-03-29OrbiMed Genesis GP LLCTenPercentOwnerSell365K$21.52$7.9M110K
2022-03-08Mack David HenryPresident and CEOExercise or conversion20K$1.37$27K47K
2021-12-30Kung WinstonCOO, CFOGift3K$0.00$07K
2021-12-15Mack David HenryPresident and CEOExercise or conversion9K$0.53$5K27K
2021-12-09Mack David HenryPresident and CEOGift40K$0.00$0188K
2021-12-09Mack David HenryPresident and CEOGift40K$0.00$040K
2021-10-06Schroeder ThiloDirectorSell800$30.15$24K1.1M
2021-10-04Schroeder ThiloDirectorSell100$30.08$3K1.1M
2021-10-01Schroeder ThiloDirectorSell12K$30.10$347K1.1M
2021-09-30Schroeder ThiloDirectorSell3K$30.03$89K1.1M
2021-09-29Schroeder ThiloDirectorSell6K$30.04$171K1.1M
2021-09-27Schroeder ThiloDirectorSell2K$30.11$53K1.1M
2021-09-22LEVINE ARNOLD JDirectorSell4K$30.00$105K410K
2021-09-22Schroeder ThiloDirectorSell100$30.00$3K1.1M
2021-09-17Schroeder ThiloDirectorSell711$30.03$21K1.1M
2021-09-13Schroeder ThiloDirectorSell13K$30.20$401K1.1M
2021-09-10Schroeder ThiloDirectorSell38K$30.44$1.2M1.1M
2021-09-10Schroeder ThiloDirectorSell5K$31.03$160K1.1M
2021-09-09Alland LeilaChief Medical OfficerExercise or conversion100$3.90$390100
2021-09-09Alland LeilaChief Medical OfficerSell100$30.25$3K0
2021-09-09Schroeder ThiloDirectorSell14K$30.31$434K1.2M
2021-09-07Alland LeilaChief Medical OfficerExercise or conversion4K$3.90$15K4K
2021-09-07Alland LeilaChief Medical OfficerSell4K$30.25$118K0
2021-09-02Schroeder ThiloDirectorSell5K$30.15$163K1.2M
2021-09-01Schroeder ThiloDirectorSell22K$30.38$668K1.2M
2021-08-31Schroeder ThiloDirectorSell20K$30.12$588K1.2M
2021-08-30Schroeder ThiloDirectorSell13K$30.05$398K1.2M
2021-08-27Schroeder ThiloDirectorSell1K$31.06$32K1.3M
2021-08-27Schroeder ThiloDirectorSell23K$30.50$714K1.3M
2021-08-26Schroeder ThiloDirectorSell6K$31.13$190K1.3M
2021-08-26Schroeder ThiloDirectorSell15K$30.39$458K1.3M
2021-08-25Schroeder ThiloDirectorSell14K$31.01$419K1.6M
2021-08-24Schroeder ThiloDirectorSell14K$31.08$450K1.6M
2021-08-23LEVINE ARNOLD JDirectorSell4K$29.50$103K413K
2021-08-23Schroeder ThiloDirectorSell700$31.06$22K1.6M
2021-08-23Schroeder ThiloDirectorSell23K$30.66$709K1.6M
2021-08-19Kung WinstonCOO, CFOExercise or conversion5K$3.22$16K7K
2021-08-19Mack David HenryPresident and CEOExercise or conversion6K$0.53$3K18K
2021-08-19Schroeder ThiloDirectorSell4K$30.97$118K1.6M
2021-08-18Schroeder ThiloDirectorSell13K$33.84$447K1.6M
2021-08-18Schroeder ThiloDirectorSell2K$34.32$77K1.6M
2021-08-18Schroeder ThiloDirectorSell11K$32.57$372K1.7M
2021-08-17Schroeder ThiloDirectorSell15K$33.21$507K1.7M
2021-08-17Schroeder ThiloDirectorSell16K$33.93$534K1.7M
2021-08-17Jalota DeepikaSVP, Regulatory Affairs and QASell3K$33.78$98K0
2021-08-17Jalota DeepikaSVP, Regulatory Affairs and QAExercise or conversion3K$3.53$10K3K
2021-08-16Schroeder ThiloDirectorSell3K$34.54$90K1.7M
2021-08-16Schroeder ThiloDirectorSell20K$33.80$662K1.7M
2021-08-13Schroeder ThiloDirectorSell26K$34.22$882K1.7M
2021-08-13Schroeder ThiloDirectorSell2K$34.66$52K1.7M
2021-08-12Schroeder ThiloDirectorSell12K$34.35$397K1.8M
2021-08-12Schroeder ThiloDirectorSell2K$34.83$69K1.7M
2021-08-11Schroeder ThiloDirectorSell34K$34.04$1.2M1.8M
2021-08-10Schroeder ThiloDirectorSell18K$34.76$622K1.8M
2021-08-10Schroeder ThiloDirectorSell3K$35.54$92K1.8M
2021-08-09Schroeder ThiloDirectorSell300$36.64$11K1.8M
2021-08-09Schroeder ThiloDirectorSell13K$35.14$466K1.8M
2021-08-09Schroeder ThiloDirectorSell9K$36.08$311K1.8M
2021-08-09Alland LeilaChief Medical OfficerExercise or conversion4K$3.90$16K4K
2021-08-09Alland LeilaChief Medical OfficerSell224$36.69$8K0
2021-08-09Alland LeilaChief Medical OfficerSell2K$32.66$67K224
2021-08-09Alland LeilaChief Medical OfficerSell2K$35.06$77K2K
2021-08-06Schroeder ThiloDirectorSell20K$36.61$721K1.8M
2021-08-06Schroeder ThiloDirectorSell200$36.94$7K1.8M
2021-08-05Schroeder ThiloDirectorSell27K$36.38$978K1.9M
2021-08-05Schroeder ThiloDirectorSell9K$36.70$321K1.9M
2021-08-04Schroeder ThiloDirectorSell2K$34.21$60K1.9M
2021-08-04Schroeder ThiloDirectorSell29K$36.22$1.0M1.9M
2021-08-04Schroeder ThiloDirectorSell17K$35.10$603K1.9M
2021-08-04Schroeder ThiloDirectorSell5K$36.80$193K1.9M

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.

Planned sales (Form 144)

Newest first. JSON

1 Form 144 notice on file for PMVP worth $1.5M at the prices reported; 0 in the last 90 days worth $0. Latest: OrbiMed Private Investments V, LP filed on 2025-10-23 to sell 1,000,000 shares ($1.5M) from 2025-10-23.

FiledSellerSharesMarket valueOf outstandingSale fromBroker
2025-10-23OrbiMed Private Investments V, LPShareholder1.0M$1.5M1.887%2025-10-23Morgan Stanley & Co. LLC

Large holders (13D and 13G)

One row per reporting person with its latest filing, newest first. JSON

9 holders report 5% or more of PMVP in their latest filing, all on Schedule 13G (passive). The largest reported stake is Srinivas Akkaraju at 9.9% of the class (7,577,467 shares), filed 2026-09-15 for an event on 2026-09-02.

FiledFormHolderSharesOf classEvent
2026-09-1513GSrinivas Akkarajuindividual7.6M9.9%2026-09-02
2026-09-1513GSamsara Opportunity Fund GP, LLCother entity3.8M5.0%2026-09-02
2026-09-1513GSamsara Opportunity Fund, L.P.partnership3.8M5.0%2026-09-02
2026-09-1513GSamsara BioCapital GP, LLCother entity3.8M5.0%2026-09-02
2026-09-1513GSamsara BioCapital, L.P.partnership3.8M5.0%2026-09-02
2026-07-2813G/Ano. 4Sio Capital Management, LLCinvestment adviser2.6M4.9%2026-06-30
2026-07-1013G/Ano. 3ArrowMark Colorado Holdings, LLCinvestment adviser2.0M3.7%2026-06-30
2026-05-1513G/Ano. 4Euclidean Capital LLCother entity2.6M4.9%2026-03-31
2026-05-1513G/Ano. 4Ashvin B. Chhabraindividual2.6M4.9%2026-03-31
2026-05-1513G/Ano. 4Marilyn H. Simonsindividual2.6M4.9%2026-03-31
2026-05-1513G/Ano. 4Greenland NFP B Ltd.other entity1.3M2.4%2026-03-31
2026-05-1513G/Ano. 4Greenland A LLCother entity347K0.7%2026-03-31
2026-05-1513G/Ano. 4Symmetry Group Ltd.other entity247K0.5%2026-03-31
2026-05-1513G/Ano. 4Greenland NFP LLCother entity66K0.1%2026-03-31
2026-03-0413D/Ano. 4ORBIMED ADVISORS LLCinvestment adviser00.0%2026-03-02
2026-03-0413D/Ano. 4ORBIMED CAPITAL GP V LLCother entity00.0%2026-03-02
2026-02-0913G/Ano. 3BML Investment Partners, L.P.partnership5.3M9.9%2025-12-31
2025-09-2313GTANG CAPITAL MANAGEMENT, LLCother entity4.7M8.9%2025-09-16
2025-09-2313GKEVIN TANGindividual4.7M8.9%2025-09-16
2025-09-2313GTANG CAPITAL PARTNERS, LPpartnership2.7M5.0%2025-09-16
2025-09-2313GTANG CAPITAL PARTNERS INTERNATIONAL, LPpartnership2.1M3.9%2025-09-16
2025-09-2313GTANG CAPITAL PARTNERS III, INCcorporation00.0%2025-09-16
2025-09-2313GTANG CAPITAL PARTNERS IV, INCcorporation00.0%2025-09-16

13F holders

Tracked managers holding PMVP at their latest 13F. JSON

2 of the 30 tracked managers held PMVP at their latest 13F, $2.7M in total at quarter-end prices. Two Sigma Investments is the largest at $2.6M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 0 cut.

FundQuarterSharesValueOf portfolioChange in shares
Two Sigma Investments2026-06-302.0M$2.6M0.00%+70K
Citadel Advisors2026-06-3047K$63K0.00%+2K

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

What this page is

PMV Pharmaceuticals in the regulatory record

Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.

Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.

This page follows PMV Pharmaceuticals (PMVP), SEC CIK 1699382, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.

Source and updates

Short interest
FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
Daily short volume
FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
Fails to deliver
SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-09.JSON and CSV
Planned sales
SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2025-10-23.JSON and CSV
Large holders
SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-09-15.JSON and CSV
13F holders
SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
Earnings dates
SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-14.JSON and CSV
Insider trades
SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2025-10-27.JSON and CSV
Company record
EDGAR filing index for CIK 1699382Ticker, name and exchange from the SEC's company list, refreshed weekly.
Rate limits
10 requests a minute without a key, 30 with a free key from a free account.

How to read it

  • Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
  • Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
  • Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.

Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.

Other companies the SEC classifies as pharmaceutical preparations

Other company pages

Datasets

Frequently Asked Questions

How much of PMVP is sold short?
2,285,070 shares were held short at the 2026-10-15 settlement, 2.3 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is PMVP's daily short volume?
On 2026-11-02, 39,268 of the 204,289 PMVP shares reported to FINRA were sold short, 19.2% of the day's reported volume. Short volume is a flow for one day, not a position.
Does PMVP have fails to deliver?
The SEC's latest file shows 623 PMVP shares failed to deliver at settlement 2026-10-09. Fails are reported per settlement date and published twice a month with a lag.
Are PMVP insiders buying or selling?
No open-market insider trades were reported for PMVP in the last 90 days. The most recent filings are listed below. Latest filing: Mack David Henry (President and CEO) on 2025-10-27.
Have PMVP insiders filed to sell?
1 Form 144 notice on file for PMVP worth $1.5M at the prices reported; 0 in the last 90 days worth $0. Latest: OrbiMed Private Investments V, LP filed on 2025-10-23 to sell 1,000,000 shares ($1.5M) from 2025-10-23.
Who owns 5% or more of PMVP?
9 holders report 5% or more of PMVP in their latest filing, all on Schedule 13G (passive). The largest reported stake is Srinivas Akkaraju at 9.9% of the class (7,577,467 shares), filed 2026-09-15 for an event on 2026-09-02.
Which tracked 13F managers own PMVP?
2 of the 30 tracked 13F managers held PMVP shares at their latest filing, $2.7M in all. The largest: Two Sigma Investments (2.0M shares, $2.6M), Ken Griffin's Citadel Advisors (47K shares, $63K).

Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.